MedTrace Logo

Megestrol Acetate Plus Rosuvastatin in Young Women With Early Endometrial Carcinoma

NCT04491643 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2025-08-11

No results posted yet for this study

Summary

To explore the treatment efficacy of megestrol acetate plus rosuvastatin in patients with early endometrial carcinoma (EEC) seeking for conservative treatment.

Conditions

  • Endometrial Carcinoma Stage I

Interventions

DRUG

Megestrol Acetate

At a dosage of 160 mg/day

DRUG

Rosuvastatin

At a dosage of 10 mg/day

Sponsors & Collaborators

  • Fudan University

    lead OTHER

Principal Investigators

  • Xiaojun Chen, PhD · Obstetrics and Gynecology Hospital, Fudan University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-09-01
Primary Completion
2023-08-11
Completion
2025-04-11

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04491643 on ClinicalTrials.gov